Renee Deming

Company: Enveda Biosciences Inc.

Job title: VP program strategy

Seminars:

Discovery of a first-in-class inflammasome pathway and multi-cytokine inhibitor for the treatment of Inflammatory Bowel Disease (IBD) 1:30 pm

DESN-X is an oral, small-molecule gut-preferred, inflammasome assembly inhibitor discovered using optimization of a natural product lead discovered via phenotypic screening of inflammasome activation ESN-X was discovered to be an allosteric modulator of HSP90 function via binding to its CTD, thereby modulating NLRP3 protein stability and inflammasome assembly ESN-X, via a putative change in client…Read more

day: day 1 post lunch track 1